vida: extract claims from 2026-05-07-all-of-us-glp1-sud-75pct-lower-odds

- Source: inbox/queue/2026-05-07-all-of-us-glp1-sud-75pct-lower-odds.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -143,3 +143,10 @@ Swedish national cohort (n=95,490) shows 47% reduction in substance use disorder
 **Source:** Osmind clinical article Q1 2026
 
 GLP-1 receptors in VTA suppress dopamine signaling through GABA neurons, functioning as 'a brake on the reward system.' This creates sustained dopaminergic modulation across ALL reward circuits—food, sex, social interaction, music, achievement—not just substance-related reward. The mechanism is tonic (continuous days-long activation) vs. phasic (natural 1-2 minute post-meal spikes), explaining both therapeutic benefit and anhedonia side effects.
+
+
+## Supporting Evidence
+
+**Source:** Abegaz et al., Frontiers in Psychiatry 2026
+
+All of Us nested case-control (n=87,494) shows OR=0.25 for any SUD with consistent effects across alcohol (OR=0.26), opioid (OR=0.31), nicotine (OR=0.32), and cocaine (OR=0.25). This is the third independent design (after Swedish within-individual and JAMA Psychiatry RCT) converging on large GLP-1 SUD effects, strengthening mechanistic inference despite observational limitations.

domains/health/glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients.md

@@ -24,3 +24,10 @@ A systematic review and meta-analysis published in eClinicalMedicine synthesized
 **Source:** Osmind clinical article Q1 2026, citing 142K participant observational study
 
 Observational data from 142,000 participants showed 75% lower odds of developing ANY substance use disorder with GLP-1 exposure (not just AUD). Semaglutide showed 85% and 87% reductions in alcohol and opioid use disorder odds. This is broader than AUD alone and represents very large effect sizes in a non-clinical population. Osmind notes these 'effect sizes exceed those historically seen with naltrexone or acamprosate' from 2025 JAMA Psychiatry trial.
+
+
+## Extending Evidence
+
+**Source:** Abegaz et al., Frontiers in Psychiatry 2026
+
+All of Us study shows 74% lower AUD odds (OR=0.26) in propensity-matched cohort (n=22,652), larger than previous 28-36% risk reduction estimates. Effect extends beyond alcohol to opioid (69% lower odds), nicotine (68% lower odds), and cocaine (75% lower odds), suggesting pan-substance mechanism rather than alcohol-specific effect.

domains/health/glp1-receptor-agonists-reduce-substance-use-disorder-odds-75-percent-across-four-substance-categories.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Three independent study designs converge on large effect sizes for SUD reduction, with observational data showing consistent 68-75 percent odds reduction across four distinct substance categories
+confidence: likely
+source: Abegaz et al., Frontiers in Psychiatry 2026; Swedish cohort Lancet Psychiatry; JAMA Psychiatry RCT 2025
+created: 2026-05-07
+title: GLP-1 receptor agonists reduce substance use disorder odds 75 percent across alcohol, opioid, nicotine, and cocaine through mesolimbic dopamine modulation
+agent: vida
+sourced_from: health/2026-05-07-all-of-us-glp1-sud-75pct-lower-odds.md
+scope: causal
+sourcer: Abegaz et al., Frontiers in Psychiatry
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+---
+
+# GLP-1 receptor agonists reduce substance use disorder odds 75 percent across alcohol, opioid, nicotine, and cocaine through mesolimbic dopamine modulation
+
+The All of Us nested case-control study (n=87,494 across four SUD cohorts) found GLP-1 receptor agonist exposure associated with OR=0.25 (95% CI 0.22-0.30) for any substance use disorder after propensity score matching and 90-day temporal lag. Effect sizes were remarkably consistent across substance categories: alcohol OR=0.26, opioid OR=0.31, nicotine OR=0.32, cocaine OR=0.25. This represents the third independent evidence stream converging on large GLP-1 SUD effects: (1) Swedish within-individual cohort (n=95,490) showed 47% SUD worsening reduction with strongest causal inference design, (2) JAMA Psychiatry RCT demonstrated 41% reduction in heavy drinking days with NNT 4.3 in AUD+obesity population, and (3) this All of Us study provides largest observational sample with broadest substance coverage. The cross-substance consistency is mechanistically coherent with GLP-1R expression in ventral tegmental area dopamine neurons that mediate reward processing across all addictive substances. The cocaine use disorder effect size (OR=0.25, 75% reduction) is particularly striking as no existing behavioral or pharmacological intervention approaches this magnitude. While observational design limits causal claims despite temporal sequencing, the convergence of three independent designs (observational, within-individual, RCT) with consistent direction across different populations and outcome definitions represents the strongest evidence pattern in the GLP-1 psychiatric literature. The lack of individual drug differentiation (liraglutide, semaglutide, exenatide, dulaglutide combined) is a significant limitation given mechanistic differences between GLP-1 agonists.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -10,20 +10,9 @@ agent: vida
 sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md
 scope: causal
 sourcer: Hendershot CS et al.
-supports:
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
-- Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison
-related:
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
-- real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial
-- semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression
-- glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-reweave_edges:
-- Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison|supports|2026-05-07
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison"]
+related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"]
+reweave_edges: ["Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison|supports|2026-05-07"]
 ---
 
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
@@ -63,4 +52,10 @@ Dr Marie Spreckley highlighted critical confound: 'All participants received CBT
 
 **Source:** eClinicalMedicine meta-analysis, 2025
 
-Semaglutide showed most consistent effects across 14 studies in meta-analysis of 5.26M patients. AUDIT score reduction of 7.81 points and 28% lower AUD diagnosis risk (HR 0.72) in real-world metabolic patient population, separate from treatment-seeking context.
+Semaglutide showed most consistent effects across 14 studies in meta-analysis of 5.26M patients. AUDIT score reduction of 7.81 points and 28% lower AUD diagnosis risk (HR 0.72) in real-world metabolic patient population, separate from treatment-seeking context.
+
+## Supporting Evidence
+
+**Source:** Abegaz et al., Frontiers in Psychiatry 2026
+
+All of Us observational data (OR=0.26 for AUD) converges with JAMA Psychiatry RCT (41% heavy drinking day reduction) and Swedish within-individual design (47% SUD worsening reduction) to form three-design convergence pattern. Cross-substance consistency (alcohol, opioid, nicotine, cocaine all 68-75% odds reduction) supports VTA dopamine mechanism that generalizes across addictive substances.

inbox/archive/health/2026-05-07-all-of-us-glp1-sud-75pct-lower-odds.md

@@ -7,10 +7,13 @@ date: 2026-03-10
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: high
 tags: [glp-1, substance-use-disorder, addiction, observational-study, all-of-us]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content